References
- Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J [Internet]. 2016 Nov 7 cited 2017 Oct 1;37(42):3232–3245. Available from: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehw334
- Biasucci LM, Liuzzo G, Angiolillo DJ, et al. Inflammation and acute coronary syndromes. Herz [Internet]. 2000 Mar cited 2017 Oct 11;25(2):108–112. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10829249
- Angiolillo DJ, Biasucci LM, Liuzzo G, et al. [Inflammation in acute coronary syndromes: mechanisms and clinical implications]. Rev Esp Cardiol [Internet]. 2004 May cited 2017 Oct 11;57(5):433–446. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15151777
- Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol [Internet]. 2012 Sep cited 2017 Sep 27;32(9):2045–2051. NIH Public Access http://www.ncbi.nlm.nih.gov/pubmed/22895665
- Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J [Internet]. 2016 Aug 1 cited 2017 Sep 27;37(29):2315–2381. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27222591
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med [Internet]. 2017 Aug 27 cited 2017 Sep 3;377:1119–1131. NEJMoa1707914 http://www.nejm.org/doi/10.1056/NEJMoa1707914
- Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med [Internet]. 2017 Aug 27 cited 2017 Sep 27;377:1319–1330. NEJMoa1709118 http://www.ncbi.nlm.nih.gov/pubmed/28844192
- Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med [Internet]. 1997 Apr 3 cited 2017 Sep 27;336(14):973–979. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9077376
- Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1. Circ Res [Internet]. 2016 Jan 8 cited 2017 Oct 11;118(1):145–156. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26837745
- Dinarello CA, Simon A, Van Der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov [Internet]. 2012 Aug 1 cited 2017 Sep 30;11(8):633–652. Available from: http://www.nature.com/doifinder/10.1038/nrd3800
- Nussinovitch U. The heart in rheumatic, autoimmune and inflammatory diseases: pathophysiology, clinical aspects and therapeutic approaches. Amsterdam (Netherlands). Elsevier Publishing Group; 2017.
- Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet [Internet]. 2017 Aug 25 cited 2017 Oct 11;390:1833–1842. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28855077
- Dhimolea E. Canakinumab. MAbs [Internet] cited. [2017 Oct 1];2(1):3–13. Available from http://www.ncbi.nlm.nih.gov/pubmed/20065636
- Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J [Internet]. 2014 Jul 1 cited 2017 Oct 11;35(27):1782–1791. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24864079